Suchergebnisse - "Tsimberidou, Apostolia-Maria"

PubPharm (164)

1

Tumor-agnostic baskets to N-of-1 platform trials and real-world data : Transforming precision oncology clinical trial design

enthalten in: Cancer treatment reviews | 2024

von Fountzilas, E. | Tsimberidou, A. | Hiep Vo, H. | +1

2

Dataset of phase I and II immunotherapy clinical trials used for a meta-analysis to assess the role of biomarkers in treatment outcomes in diverse cancers

enthalten in: Data in brief | 2023

von Fountzilas, E. | Hiep Vo, H. | Mueller, P. | +2

3

Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors

enthalten in: British journal of cancer | 2023

von Tsimberidou, A. | Verschraegen, C. | Wesolowski, R. | +3

4

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

enthalten in: Cancer chemotherapy and pharmacology | 2023

von Piha-Paul, S. | Tseng, C. | Tran, H. | +13

5

Correlation between biomarkers and treatment outcomes in diverse cancers : a systematic review and meta-analysis of phase I and II immunotherapy clinical trials

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Fountzilas, E. | Vo, H. | Mueller, P. | +2

6

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

enthalten in: Cancer chemotherapy and pharmacology | 2023

von Piha-Paul, S. | Tseng, C. | Tran, H. | +13

7

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

enthalten in: Cancer chemotherapy and pharmacology | 2023

von Piha-Paul, S. | Tseng, C. | Tran, H. | +13

8

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

enthalten in: Cancer chemotherapy and pharmacology | 2023

von Piha-Paul, S. | Tseng, C. | Tran, H. | +13

9

First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors

enthalten in: JCO precision oncology | 2023

von Tsimberidou, A. | Vo, H. | Beck, J. | +3

10

Biomarkers and Outcomes in Diverse Cancers: Meta-Analysis of Early Phase Immuno-Oncology Trials

enthalten in: ResearchSquare.com | 2022

von Fountzilas, E. | Vo, H. | Mueller, P. | +2

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[17]